Follow the 티앤알바이오팹 stock price and the full management transaction log of the company, a listed equity based in South Korea. Shares are quoted on the KR market, under the authority of DART (FSS). Operating in the Health Care sector, 티앤알바이오팹 has recorded 107 insider filings. Market capitalisation: €126.5bn. The latest transaction was reported on 30 June 2026 (Purchase). Among the most active insiders: 윤원수. The full history is accessible without an account.
107
Insider Decl.
n/a
Thresholds
€280,357
24 ops.
Buy Volume
n/a
3 ops.
Sell Volume
30Σ signal
Buys €280,357n/a Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 27,376 of 28,752 companies
15.5
score / 100
Value
13
Quality
18
FCF yld-8.5%
Earn yld-30%
EV/EBITDA·
ROE-146%
Gross mgn26%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
티앤알바이오팹 is a company specializing in the health and pharmaceutical sector, listed on the XKRX market. It focuses on developing innovative technologies in the biopharmaceutical field.
